SBI Life Insurance Company · risk themes across the available quarters.
Bear-case history
GST drag of ~110-120bps expected to continue for next 2.5 months (until mid-September) on prorated basis. Stamp duty increase also contributing to elevated other expenses corresponding to higher sums assured being written.
Individual protection AP growth at ~18% appears softer vs competitors reporting stronger numbers. Management attributes this to strategic shift toward lower-ticket pure term products (41% growth) from ROP (return of premium) products, resulting in lower absolute APE while improving product quality.
61st month persistency showing decline as COVID-era cohort (policies sold during COVID period) moves through persistency buckets. Management expects this cohort to exit by Q3 FY27, with persistency normalizing thereafter.
Analyst raised concern about differing street views on regulatory landscape for non-par products. Management remained vague, stating only that regulations will be 'for betterment' and they are 'waiting and watching' on upcoming regulatory changes.
The removal of input tax credit on individual business segments creates ~1.74% annualized margin headwind on new business written after September 22, 2025. Renewal premium business also faces GST impact as input credits are no longer available, affecting the existing book.
Agency and bank channels delivered only 7% and 7% growth respectively versus management's expectations, requiring scheme tweaks and distributor re-engagement in September. While September recovered to 15%, sustained execution remains critical to meet full-year 13-14% growth targets.
OPEX ratio increased to 6.2% vs 5.8% YOY due to planned expansion (44 new branches, 3,500+ employee additions). Total cost ratio rose to 10.9% from 10.6%, creating margin dilution risk if premium growth moderates.
Protection business has longer profit recognition periods. As protection mix expands above 10% of APE, a greater portion of profits will be deferred, potentially constraining PAT growth relative to premium growth in the medium term.
The 61st month persistency cohort (COVID-affected policies) declined as expected, though management termed it the 'last cohort' to impact results. Other cohorts (25th, 37th, 49th month) showed marginal or expected performance.
ULIP mix increased from 72% to 68% year-over-year which partially offsets GST impact but represents unfavorable mix shift. Management expects this to normalize as PAR/non-PAR products gain traction.
Solvency ratio at 1.91x (vs regulatory minimum of 1.50x) has declined from historical levels due to protection mix and VNB growth. While management remains comfortable, dividend payout in Q4 could add 10-15 percentage point pressure.
Agency productivity at ₹3 lakh per agent lags SBI bank productivity of ₹6.4 million by significant margin. Despite adding 94,000 agents, productivity improvement is gradual, creating opex pressure as evidenced by 90bps rise in opex ratio.